WALTHAM, MA–Dash Bio has expanded its Massachusetts operations with a new 24,000-square-foot, GLP-compliant laboratory facility in Waltham, marking a more than fivefold increase in space as the company scales its bioanalysis platform.
The bioanalysis contract research organization announced it has moved into the facility at 21 Hickory Drive, which is already operational and accepting projects. The expansion significantly increases Dash Bio’s capacity for sample storage, instrumentation and automated workflows designed to accelerate turnaround times for pre-clinical and GLP-compliant bioanalysis.
The new Waltham lab supports Dash Bio’s model of delivering results in days rather than the weeks or months typical of traditional CROs. The company said the facility is purpose-built for automation, replacing manual processes with standardized, technology-driven workflows aimed at improving speed, consistency and predictability.
“This facility gives us the capacity to serve more biotech companies who are tired of waiting months for data that should take days,” CEO Dave Johnson said in a statement. Johnson previously served as chief data and AI officer at Moderna.
Founded in 2024, Dash Bio has raised $17.5M and is targeting biotech companies seeking faster development timelines and more transparent pricing. The Waltham expansion positions the company to serve a growing customer base in Greater Boston, one of the country’s largest biotech hubs, as demand continues to rise for lab infrastructure that can support faster drug development cycles.
